$176 Million is the total value of TRV GP II, LLC's 4 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JNCE | JOUNCE THERAPEUTICS, INC. | $78,364,000 | -65.7% | 10,230,349 | 0.0% | 44.43% | +3.7% | |
| BPMC | Sell | BLUEPRINT MEDICINES CORPORATION | $55,791,000 | -75.2% | 878,875 | -64.2% | 31.63% | -25.0% |
| ALNA | ALLENA PHARMACEUTICALS, INC. | $36,366,000 | +18.2% | 2,790,964 | 0.0% | 20.62% | +257.7% | |
| SAGE | SAGE THERAPEUTICS, INC. | $5,848,000 | -2.8% | 37,362 | 0.0% | 3.32% | +194.0% | |
| MYOK | Exit | MYOKARDIA, INC. | $0 | – | -885,104 | -100.0% | -8.09% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Mark Levin #1
- Kevin P. Starr #2
- Robert I. Tepper #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JOUNCE THERAPEUTICS, INC. | 20 | Q3 2022 | 100.0% |
| ALLENA PHARMACEUTICALS, INC. | 19 | Q2 2022 | 24.4% |
| BLUEPRINT MEDICINES CORPORATION | 6 | Q1 2019 | 47.1% |
| REVOLUTION MEDICINES, INC. | 5 | Q1 2021 | 55.4% |
| SAGE THERAPEUTICS, INC. | 5 | Q4 2018 | 16.3% |
| MYOKARDIA, INC. | 2 | Q1 2018 | 21.9% |
View TRV GP II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-05 |
| 4 | 2021-09-17 |
| 13F-HR | 2021-08-11 |
| 4 | 2021-06-14 |
| 4 | 2021-06-07 |
| 4 | 2021-05-27 |
View TRV GP II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.